Loading...
•
Jun 30
Alkermes Q2 2025 Earnings Report
Alkermes posted strong Q2 2025 results with growth across proprietary products and continued profitability.
Key Takeaways
Alkermes reported total revenue of $390.7 million and GAAP net income of $87.1 million in Q2 2025, driven by double-digit growth in LYBALVI, ARISTADA, and VIVITROL. The company maintained robust operating margins and reiterated its 2025 financial guidance.
Total proprietary net sales reached $307.2 million, led by LYBALVI, ARISTADA, and VIVITROL.
GAAP net income was $87.1 million with diluted EPS of $0.52.
Adjusted EBITDA totaled $126.5 million, reflecting strong operational efficiency.
Cash, cash equivalents, and investments increased to $1.05 billion.
Alkermes
Alkermes
Alkermes Revenue by Segment
Revenue by Segment
VIVITROL Revenue
CapyFin.comARISTADA Revenue
CapyFin.comLYBALVI Revenue
CapyFin.comVUMERITY Revenue
CapyFin.comJNJ Royalties Revenue
CapyFin.com Forward Guidance
Alkermes reiterated its 2025 financial expectations with confidence in sustained growth across its proprietary portfolio and continued profitability.
Positive Outlook
- Strong proprietary product performance led by LYBALVI and ARISTADA.
- Adjusted EBITDA exceeded $126 million, supporting robust margins.
- Cash position strengthened to over $1.05 billion.
- Positive clinical data from Vibrance-1 boosts narcolepsy program outlook.
- Phase 3 program initiation planned for alixorexton (ALKS 2680).
Challenges Ahead
- Total revenue declined slightly from $399.1M to $390.7M YoY.
- Manufacturing and royalty revenues fell significantly YoY.
- Higher R&D expenses impacted margins.
- SG&A remained flat, showing limited leverage despite revenue pressure.
- No upward revision in guidance despite strong quarter.